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Background: The aim of this study was to compare acute effects of turnip rapeseed oil rich with mono‑ and polyun‑
saturated fatty acids and cream on postprandial triglyceride levels and post‑glucose load measures of insulin sensitiv‑
ity in population of men with metabolic syndrome.
Methods: This open‑label balanced crossover study included 37 men with metabolic syndrome. They underwent an 
oral glucose‑fat tolerance test where they ingested 75 g of glucose with either 240 mL of cream or 84 mL of turnip 
rapeseed oil depending on the study arm. Hourly postprandial blood samples were drawn up to 5 h after this oral 
glucose‑fat tolerance test to determine the changes in triglyceride concentrations and to measure insulin sensitiv‑
ity. Changes in insulin sensitivity were calculated with different insulin sensitivity indices (OGIS, Stumvoll, Gutt and 
McAuley scores) derived from measured insulin and glucose concentrations. The oral glucose‑fat tolerance test was 
preceded by a period during which the participants consumed a daily portion of either 35 mL of turnip rapeseed oil 
or 37.5 g of butter depending on the study arm in addition to their habitual diets. Both dietary periods lasted from 
6 to 8 weeks. After an 8‑week wash‑out period the subjects crossed over to the other study arm and underwent the 
same process with the other fat adjunct.
Results: The area under the curve for hourly triglyceride concentrations was 16% smaller after turnip rapeseed oil 
than after cream (13.86 [interquartile range 8.54] vs. 16.41 [9.09] mmol/l, p < 0.001). The insulin sensitivity markers of 
OGIS (324 [38.97] vs. 377 [68.38] p < 0.001), Stumvoll score (0.079 [0.029] vs. 0.085 [0.029], p = 0.038) and Gutt score
(67.0 ± 2.78 vs. 78.8 ± 4.97 p = 0.001) were higher after turnip rapeseed oil period than after butter period. There was a
non‑significant change in the McAuley score.
Conclusion: Dietary turnip rapeseed oil improved postprandially measured insulin sensitivity and triglyceride con‑
centrations compared to cream and butter. This provides a possible efficient dietary mean to treat cardiovascular risk 
factors.
Trial registration ClinicalTrials.gov NCT01119690 (05‑06‑2010)
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Background
Patients with metabolic syndrome (MetS) are at increased 
risk of type 2 diabetes mellitus, cardiovascular disease 
and mortality in coronary heart disease [1–3]. MetS is 
characterised by increased waist circumference followed 
by elevated blood pressure (BP), fasting hyperglycaemia 
and dyslipidaemia [4]. According to recent data from a 
study with well-matched pairwise comparisons, MetS is 
associated with impaired arterial function independently 
of classical risk factors except those included in MetS 
definition [5]. The main problem with MetS is the imbal-
ance of energy intake and expenditure, but the quality of 
diet is also of great importance according to animal and 
human studies [6–8]. Studies have shown that n − 3 poly-
unsaturated fatty acids (PUFA) reduce plasma triglycer-
ide (TG) concentrations through reduced endogenous 
very low density lipoprotein (VLDL) production [9, 10]. 
This might account for the reduced postprandial lipemic 
response following n − 3 PUFA supplementation [11].
Insulin resistance means decreased sensitivity or 
responsiveness to the metabolic actions of insulin. Insu-
lin resistance results from both genetic and environ-
mental factors, and it has a major role in the risk for 
cardiovascular disease (CVD) associated with diabetes 
and MetS [12, 13]. The gold standard method for assess-
ing insulin resistance is the hyperinsulinemic glucose 
clamp technique first introduced by DeFronzo et al. [14]. 
The clamp technique has been found laborious since it 
requires insulin infusion and repeated blood sampling. 
This has led to the creation of several more practical indi-
ces to estimate insulin sensitivity. Usually these indices 
utilize fasting and postprandial concentrations of glucose 
and insulin obtained during conventional oral glucose 
tolerance tests (OGTT) [15]. These methods are rela-
tively simple and more suitable for large scale epidemio-
logical studies than the hyperinsulinemic glucose clamp 
technique.
TG and cholesterol concentrations have traditionally 
been measured after an 8 h fast, but it has been shown 
that also non-fasting TG concentration is a strong and 
independent predictor of future myocardial infarction 
[16]. Nowadays the European Society of Cardiology has 
stated in its latest guideline for the management of dys-
lipidemias that non-fasting lipid concentrations can be 
used in screening and in general risk estimation [17].
In our earlier study we found that in men with MetS 
a small modification of the diet with cold-pressed tur-
nip rapeseed oil (CPTRO) containing a high amount 
of monounsaturated fatty acids (MUFA) and PUFA 
decreased the concentration of circulating low-density 
lipoprotein (LDL) cholesterol, oxidized LDL and total 
cholesterol when compared to butter, which contains a 
high amount of saturated fatty acids (SFA) [18]. However, 
the modification had no significant effect on the fasting 
concentrations of high-density lipoprotein (HDL) cho-
lesterol, triglycerides, glucose or glycated haemoglobin 
(HbA1c). In a supplementary study the reduction of LDL 
cholesterol could not be explained by changes in whole-
body cholesterol or PCSK9 metabolism [19].
Turnip rapeseed oil is an essential source of dietary 
plant-derived PUFA in the North-European diet and 
widely available. However, the knowledge of the effects of 
CPTRO on insulin sensitivity and postprandial triglycer-
ide concentrations is very limited. The aim of this study 
was to compare the acute effects of CPTRO and cream 
on post-glucose load measures of insulin resistance and 
postprandial response to a fat load among men with 
MetS.
Methods
To compare acute effects of CPTRO and cream with 
each other we carried out a balanced, randomized 
crossover study with two different dietary interven-
tion protocols. Thirty-seven men with MetS according 
to the National Cholesterol Education Program (NCEP) 
Adult Treatment Panel III criteria [4] accomplished the 
clinical phase of this study. The mean age of the partici-
pants was 53.5 (35–65) years. Twenty-one subjects had a 
diagnosis of arterial hypertension and six had coronary 
heart disease. Six men were active smokers, 22 were for-
mer smokers and nine were non-smokers. Four subjects 
were on diabetes medication, 15 subjects were using sta-
tin medication and two of these had combination ther-
apy of statin and fibrate. Characteristics of the subjects 
[mean ± standard deviation (SD)] were as follows: BP 
145.5 ± 12.3/90.8 ± 5.6  mmHg, Body Mass Index (BMI) 
31.0 ± 5.0, and HbA1c 46.7 ± 7.2 mmol/mol.
The study is a part of Hämeenlinna Metabolic Syn-
drome research program (HMS), which is a regional 
entity investigating atherosclerotic risk factors in men 
with MetS [20].
Design and diets
Acute effects of two different glucose-fat loads were stud-
ied. The study subjects underwent a standardized com-
bined oral glucose and fat tolerance test in a randomized 
balanced crossover setting. The glucose load was a stand-
ard 75  g oral glucose of OGTT but in this case com-
bined with a lipid charge of either 240 mL of cream (35% 
fat) (Valio Ltd, Finland) or 84  mL of CPTRO  (VirginoR, 
Kankaisten Öljykasvit Ltd, Finland).
Both acute glucose-fat loads were preceded by a differ-
ent dietary period with duration of 6–8 weeks [18]. The 
subjects who were to have a glucose-fat drink containing 
cream ingested a daily 37.5 g of butter on the SFA period 
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and the subjects bound to have a glucose-fat drink con-
taining CPTRO had a daily supplementation of 35 mL of 
CPTRO  (VirginoR) on the oil period. Both were provided 
free of charge. After the first period all subjects had an 
8-week wash-out period before changing to the oppo-
site arm for a period of 6–8  weeks (Fig.  1). Otherwise 
the subjects stayed on their habitual diet and maintained 
their usual level of physical activity.
Blood sampling
Fasting blood samples were drawn between 8:00 and 
9:00 a.m. after an overnight fasting and after at least 
10-min rest in sitting position. Blood samples after glu-
cose-fat load were drawn at the time points of 60, 120, 
180, 240 and 300 min to measure the concentrations of 
glucose, insulin and TG. Samples for determination of 
TG and glucose were collected into 5  mL lithium-hep-
arin gel tubes and 2  mL sodium-fluoride tubes, respec-
tively. Samples for insulin determination were allowed to 
clot 30  min in room temperature before centrifugation 
(2000g, 10  min) after which serums were transferred to 
secondary tubes and stored at − 70 °C until analysed.
Biochemical analysis
Concentration of serum TG was analysed enzymatically 
without delay in the hospital by using Cobas Integra pro-
cedure (Roche). Plasma glucose was measured by using 
the glucose dehydrogenase method. Frozen samples for 
insulin determination were allowed to reach room tem-
perature, centrifuged again (2000g, 10 min) and analysed 
all in the same patch. Serum insulin was analysed by using 
simultaneous one-step immunoenzymatic (“sandwich”) 
assay by UniCel DxI 800 analyser (Beckman Coulter™, 
California, USA) and by  AccessR Immunoassay Systems 
(Beckman Coulter™), ultrasensitive insulin (REF 33410) 
assay. A sample was added to a reaction vessel along with 
mouse monoclonal anti-insulin alkaline phosphatase 
conjugate and paramagnetic particles coated with mouse 
monoclonal anti-insulin antibody. The serum insulin 
binds to the antibody on the solid phase, while the con-
jugate reacts with a different antigenic site on the insulin 
molecule. After incubation in a reaction vessel, materials 
bound to the solid phase were held in a magnetic field 
while unbound materials are washed away. Then, the 
chemiluminescent substrate Lumi-Phos*530 was added 
to the vessel and light generated by the reaction is meas-
ured with a luminometer. The light production is directly 
proportional to the concentration of insulin in the sam-
ple. The amount of insulin in the sample was determined 
from a stored, multi-point calibration curve. The meas-
ured analyte in the  AccessR ultrasensitive insulin calibra-
tors is traceable to the WHO 1st International Reference 
preparation 66/304. Traceability process is based on 
prEN ISO 17511. In our laboratory, coefficient of varia-
tion (CV  %) for serum insulin was 1.5 (within run) and 
4.9–6.0 (between runs).
The measurements were carried out in the Clinical 
Laboratory of Kanta-Häme Central Hospital. Research 
personnel performing the laboratory measurements were 
blinded about the diet periods. Area under curve from 
0 to 5 h (AUC 0–5h), was calculated for concentrations of 
plasma glucose, insulin and serum TG. Assessment of 
insulin resistance and sensitivity were performed by the 
oral glucose insulin sensitivity index (OGIS), McAuley 
index, Stumvoll index and Gutt index. These formulae 
were carried out according to the original methods [21–
24] and are presented in Table 1.
OGIS was calculated using an Excel spreadsheet for 
3-h OGTT available on the original webpage [25]. The 
laboratory practiced strict internal quality control with 
daily control samples and taking successfully part in the 
national external quality assurance program (Labquality 
Oy) with monthly control samples.
Fig. 1 Study design. Design of the open, randomized cross‑over study. OGFTT oral glucose‑fat tolerance test containing 75 g of glucose and 
portion of either CPTRO or cream
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Statistical methods
We made a priori a sample size calculation for the end 
points now studied. For the effect of 7% (SD of the 
change = 0.14; alpha = 0.05, 2-tailed), we needed 31–32 
patients to yield power of 80%. Statistics were analysed 
with IBM SPSS Statistics 23. The Kolmogorov–Smirnov 
and Shapiro–Wilk tests were used to test the data for 
normal distribution. The effects of two different fat-glu-
cose tests were compared with paired samples’ T test in 
case of normality and non-parametric Wilcoxon rank 
sign test for dependent samples in case of non-normal-
ity. The p-value of < 0.05 was regarded as statistically 
significant. P-values equal to or greater than 0.05 are 
noted as non-significant (NS). Results are presented as 
mean ± standard error of the mean (SEM) for normally 
distributed data and as median and interquartile range 
(IQR) for non-normality.
Results
One subject had to be excluded from the analysis of insu-
lin sensitivity due to missing insulin values. Although 
fasting TG concentrations did not differ from each 
other between the two periods, the AUC of TG was 16% 
smaller after the acute administration of glucose with 
CPTRO than after glucose with cream (p < 0.001) (Fig. 2a, 
Table  2). The rise in the plasma glucose was greater at 
60  min after the glucose-CPTRO administration than 
after glucose-cream. After this point, the plasma glucose 
concentration diminished more strongly and remained 
lower after the glucose-CPTRO administration than after 
glucose-cream (Fig. 2b). Because of the different profiles 
of plasma glucose, the AUC of glucose concentration 
after two different fat loads did not differ significantly 
from each other. The AUC of plasma insulin was lower 
after glucose-CPTRO than after glucose-cream (p = 0.03) 
(Fig. 2c).
Insulin sensitivity scores with the methods of OGIS, 
Stumvoll, and Gutt were significantly higher after the 
glucose-CPTRO than after glucose-cream, by 16% 
(p < 0.001), 7% (p = 0.038), 18% (p = 0.001), respectively 
(Table 2).
There was no significant difference in the insulin sen-
sitivity with the method of McAuley. A higher value of 
all these indices indicates better insulin sensitivity. The 
insulin sensitivity estimations were carried out also with-
out subjects with diabetes leading to significantly higher 
OGIS and Gutt score after the glucose-CPTRO than after 
glucose-cream, by 16% (p = 0.003) and 22% (p = 0.006), 
respectively. The difference of Stumvoll insulin sensitivity 
index between the intervention groups was non-signifi-
cant when diabetic subjects were excluded. Altogether 
these findings imply that insulin sensitivity was better 
after acute ingestion of CPTRO than that of cream.
Discussion
The main novel finding in this balanced, randomized 
cross-over intervention study was that replacing SFA 
from cream with MUFA and PUFA from CPTRO is asso-
ciated with significant improvement in postprandial sur-
rogate marker indices of insulin sensitivity and smaller 
postload TG concentrations among men with MetS. 
Our result is a consequence of acute glucose-fat load 
combined with small diet modification over preceding 
6–8 weeks.
The significant improvement of insulin sensitivity is in 
accordance with earlier studies regarding daily supple-
mentation of PUFA [26–28]. The accurate mechanism 
through which unsaturated fatty acids might influence 
glucose homeostasis is still unclear. It seems that benefi-
cial effects of n − 3 PUFA on insulin sensitivity of obese 
subjects might be related to a decrease of plasma glu-
cose-dependent insulinotropic polypeptide (GIP) [26], 
an incretin hormone released from the intestinal K-cells 
in response to the presence of nutrients in the intesti-
nal lumen [29]. Another possible explanation for the 
beneficial effects of n − 3 PUFA on insulin sensitivity is 
the increased level of circulating adiponectin noticed in 
experimental animal studies [30, 31]. In human studies 
fish oil supplementation moderately increased circulat-
ing adiponectin [32], but a study by Ramezani et al. found 
that 8  weeks of omega-3 fatty acids alone didn’t cause 
Table 1 The insulin sensitivity indices
Subscript numbers refer to minutes of OGTT and subscript letter m to mean fasting and 2-h concentrations. Units are mmol/L for glucose except mg/dL for Gutt, 
mmol/L for TG, mU/L for insulin except pmol/L for Stumvoll and kg for body weight
G glucose, I insulin, TG triglyceride
Index Formula References
OGIS Complex formula requiring  G0,  G120,  G180,  I0,  I120 and  I180 (3 h OGTT) or G0,  G90,  G120,  I0,  I90 and  I120 (2 h OGTT). 
The formula includes six constants
[21]
McAuley exp[2.63 − 0.28ln(I0) − 0.31ln(TG0)] [22]
Stumvoll 0.222 − 0.00333 × BMI − 0.0000779 × I120 − 0.000422 × age [23]
Gutt m/[Gm × log10(Im)], in which m = [75 000 mg + (G0 − G120) × 0.19 × body weight]/120 min [24]
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significant changes in serum adiponectin concentrations, 
unlike the combination of omega-3 fatty acids and vita-
min E supplementation [33]. A recent prospective rand-
omized placebo-controlled trial by Poreba et al. showed 
that daily 2 g dose of n − 3 PUFA did not have any effect 
on adiponectin, total cholesterol, LDL or TG in tradi-
tional fasting samples among patients with type 2 diabe-
tes and established vascular disease [34].
Screening of dyslipidaemias and general cardiovas-
cular risk estimation via non-fasting blood samples is 
more convenient and flexible method for the patients 
than the traditional 8-h fasting. It has also been criti-
cized that the traditional measuring of TG after 8-h fast 
doesn’t assess the dominant daily state when it is taken 
into consideration that normal Western diet consists of 
three major meals a day with possible snacks in between, 
which means that the 8-h fast for traditional TG measur-
ing prevails only during few morning hours [35]. On the 
other hand, it has been shown that when compared with 
fasting concentrations the actual non-fasting TG concen-
trations have similar or even stronger association with 
CVD [36–39], and that the magnitude of TG response is 
a better indicator of coronary artery disease risk than the 
fasting TG concentration [40]. This association has been 
held controversial, since the higher risk of CVD has been 
omitted to low concentrations of protective HDL, which 
for one is strongly associated with elevated TG concen-
trations. The HDL-hypothesis is not supported by the 
fact that several randomized clinical trials of HDL-cho-
lesterol raising drugs have failed to show a reduction in 
cardiovascular events [41, 42]. It has been proposed that 
an easily reproducible standard test meal might be useful 
in assessing CVD risk once standard reference values for 
postprandial TG have been developed [37].
It has to be emphasized, that our study was not limited 
to sole acute effects of glucose-fat load. During the pre-
ceding weeks the habitual diet was supplemented with 
the lipid charges studied in the oral tolerance test in a 
crossover design. Therefore, the present results form a 
combination of a limited dietary modification for nearly 
2  months and the acute oral glucose-fat tolerance test. 
Our choice to combine two study protocols (i.e. acute 
load and longer-lasting diet) might be arguable. How-
ever, in this way we wanted to simulate the everyday situ-
ation, where baseline diet acts together with the acute 
ingestion of food. Present results deepen our earlier find-
ings, where supplementation of habitual diet with cold-
pressed  VirginoR turnip rapeseed oil was followed with 
diminished concentrations of fasting total and LDL cho-
lesterol and especially that of oxidized LDL [18].
The strength of our study is the relatively high num-
ber of study subjects in this crossover study. It is usual 
for this kind of dietary human studies to be limited to 
Fig. 2 Fasting and postprandial concentrations of TG, glucose and 
insulin. The continuous curve represents measured concentrations 
after cream and the dashed curve represents measured 
concentrations after CPTRO
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fewer subjects and parallel groups setting. The higher 
number of subjects and the cross-over setting instead 
of parallel one allow us to get more precise picture 
of the results after two different fat loads as the bal-
anced crossover design minimizes the variability of 
results. Some of the participants were smokers or on 
lipid lowering medication, but the number of smok-
ers was similar during both periods as the study was 
performed in a crossover design. This means that each 
crossover participant served as his own control. The 
same applies for participants on lipid lowering medica-
tion. The daily fat and energy intake was not measured 
with dietary records, but the subjects filled a detailed 
questionnaire at the end of the intervention periods to 
confirm the habitual physical activity and diet during 
the study. This kind of a food frequency questionnaire 
has been reported earlier to be an applicable means for 
ranking energy and food intake [43]. No significant dif-
ference was seen in the weight of the subjects between 
the two dietary periods, which is in accordance with 
previous studies on diets enriched with n − 3 PUFA and 
MUFA [44, 45], so it is unlikely that our findings could 
be explained by imbalanced energy intake. The collec-
tion of postprandial samples was extensive enough to 
reveal differences between the groups as it has been 
reported that the peak of TG concentrations is gener-
ally reached 4 h after consumption [46] and that when 
it comes to measuring postprandial TG concentrations, 
the concentrations measured between 2 and 4  h have 
the strongest association with cardiovascular events 
[38]. It is interesting that the insulin sensitivity indices 
utilizing glucose and insulin concentrations measured 
after acute glucose-fat load produced improved insu-
lin sensitivity levels, whereas the index utilizing solely 
fasting concentrations led to non-significant difference. 
This finding is in accordance with the glucose concen-
tration curves presented in Fig. 2b. It is unclear why the 
difference in estimated insulin sensitivity between the 
intervention groups was even bigger when diabetic sub-
jects were excluded.
A limitation in our study was that we didn’t measure 
plasma GIP or circulating adiponectin of the subjects, 
nor did we perform aforesaid glucose-fat tolerance test 
at the baseline to measure insulin sensitivity. It has also 
been stated that considering postprandial investigations 
such as our study the issues relating to the preprandial 
fast and the timing of fat ingestion represent key issues 
that may affect the postprandial response but do not nec-
essarily reflect a free-living situation. As described earlier, 
in our study both fasting and post-load blood samples 
were taken according a standardised protocol.
It would also have been useful to have groups with 
different amounts of CPTRO to investigate what is the 
required amount of CPTRO in the acute glucose-fat 
load for these beneficial effects to occur. The study only 
included men with MetS, so the results cannot be gen-
eralized to appear in the whole population although 
men with MetS are abundant and in a clearly increased 
risk for atherosclerotic cardiovascular diseases. It is also 
possible that the relatively short intervention period of 
6–8 weeks preceding acute glucose-fat load was not long 
enough for the induced effects of altered gene expression 
to appear. The subjects were not blinded regarding the 
fat adjunct used at the time because of the nature of the 
intervention. Isocaloric dietary periods with all nutrition 
measured and delivered from single producer e.g. hospi-
tal kitchen would produce more precise results but this 
would likely lead to fewer participants and increase in 
non-compliance.
The calculable insulin sensitivity indices are conven-
tionally used in large-scale epidemiologic studies. The 
indices are not as precise estimates of insulin sensitivity 
as the glucose clamp technique, but they give a decent 
estimation of insulin sensitivity.
As the prevalence of MetS increases worldwide we are 
in dire need of CVD preventing means. When it comes to 
lifestyle interventions, modification of dietary habits is a 
method relatively easy to replicate and implement exten-
sively. Choosing oils containing MUFA and PUFA over 
cream or butter containing SFA offers an inexpensive and 
easily approachable option to improve insulin sensitivity 
and TG concentrations postprandially. The subjects are 
not required to consume certain foods multiple times 
a day but to simply exchange from one quality of fat to 
another.
Conclusions
Acute effects of cold-pressed turnip rapeseed oil com-
pared to cream improved insulin sensitivity and TG 
concentrations measured postprandially, two key 
Table 2 Assessment of insulin sensitivity and triglyceride 
concentration AUC from samples collected 
during the OGFTT
a Values shown are median and IQR except mean and standard deviation for 
Gutt and McAuley indices
b AUC of triglyceride concentrations is up to 5 h after the OGFTT
Variablea Cream CPTRO p
n = 37 n = 37
AUC  triglyceridesb 16.41(8.54) 13.865(9.09) < 0.001
OGIS 324 (38.97) 377 (68.38) < 0.001
Stumvoll 0.079 (0.029) 0.085 (0.028) 0.038
Gutt 67.0 ± 2.78 78.8 ± 4.97 p = 0.001
McAuley 5.68 ± 0.20 5.96 ± 0.20 NS
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factors in the innermost core of MetS and CVD. Thus, 
changing fat quality from SFA towards MUFA and 
PUFA provides an efficient dietary means to improve 
blood lipid profile and battle insulin resistance in the 
vast number of men with MetS.
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